A Cure in Sight
๐Ÿ’™ Calling All Uveal Melanoma Patients โ€” Especially IDE196 Trial Participants ๐Ÿ’™ Your experience holds the key to advanc

6 likes

๐Ÿ’™ Calling All Uveal Melanoma Patients โ€” Especially IDE196 Trial Participants ๐Ÿ’™ Your experience holds the key to advancing future treatments.

Researchers Riz Haq (Dana-Farber) and Justin Moser (Honor Health) are working with A Cure In Sight to understand how and why some uveal melanoma tumors become resistant to darovasertib/crizotinib (IDE196). To unlock those answers, we need your help. ๐Ÿ”ฌ If you have EVER been on the IDE196 trial โ€” even for just 1 or 2 doses: You may have biopsy samples from your routine care that could help researchers make the next breakthrough. No new biopsies are needed. Simply allowing access to samples that already exist can accelerate discoveries for the entire community. ๐Ÿ’™ How You Can Make a Difference Right Now: 1๏ธโƒฃ Join the Insight Biobank: ๐Ÿ‘‰ https://pattern.org Select Uveal Melanoma โ€“ Darvo-Criz IDE196 when registering. 2๏ธโƒฃ Enroll in the Insight Registry: ๐Ÿ‘‰ https://insight.iamrare.org Completing the surveys adds powerful clinical context to your samples, multiplying their impact. Why It Matters Every contribution helps researchers map resistance, refine treatments, and bring us closer to more effective therapies. Whether youโ€™re currently on IDE196, participated in the past, or are part of the broader UM communityโ€”your data and samples can change outcomes for future patients. Thank you for being a vital part of this effort and for standing with us in the fight against uveal melanoma. ๐Ÿ’™ Together, we move research forward.
See it on Instagram โ†—